TL;DR
This paper introduces an in-silico saturation mutagenesis approach to predict how mutations in the beta subunit of RNA polymerase (RNAP) in Mycobacterium leprae affect its stability and interaction with rifampin. This computational method offers a rapid way to identify potentially detrimental mutations that confer drug resistance, bypassing the lengthy experimental validation currently used.
What Problem Does This Paper Address?
Rifampin resistance is a major challenge in treating leprosy, and its diagnosis often relies on identifying mutations in the rpoB gene, which encodes the RNAP beta subunit. However, current methods for confirming drug resistance are time-consuming and impractical for routine diagnostics. Mouse footpad experiments, the gold standard for phenotypic resistance testing, can take 8-12 months. This leaves a critical gap in understanding the molecular mechanisms behind emerging drug resistance and in developing rapid diagnostic tools. The authors aim to bridge this gap by computationally predicting the structural and functional consequences of all possible mutations in the M. leprae RNAP beta subunit, providing a faster way to assess their impact on rifampin binding and overall protein stability.
Methods
The study employs a comprehensive in-silico saturation mutagenesis strategy. This involves:
- Comparative Protein Modeling: A 3D model of the M. leprae RNAP beta subunit was built using existing crystal structures of homologous proteins.
- Saturation Mutagenesis: Every residue in the beta subunit (1126 residues) was computationally mutated to all 19 other amino acid types, generating a total of 21,394 potential mutations.
- Stability and Interaction Prediction: A suite of computational tools was used to predict the impact of these mutations on:
- Thermodynamic Stability: Tools like mCSM, SDM, and FoldX were employed to estimate changes in Gibbs free energy.
- Protein-Protein Interfaces: mCSM-ppi was used to assess the effect on interactions between the beta subunit and other RNAP subunits.
- Protein-Nucleic Acid Interactions: mCSM-NA2 was used to predict changes in affinity with RNA.
- Protein-Ligand Interactions: mCSM-lig was used to predict changes in affinity with rifampin, specifically for residues within 10 Å of the drug's binding site.
- Vibrational Entropy and Normal Mode Analysis: ENCOM and DynaMut were used to assess the impact of mutations on protein flexibility and vibrational entropy.
- Residue Conservation Analysis: CONSURF was used to map evolutionary conservation onto the protein structure, helping to identify functionally important regions.
- Structural Analysis: Tools like Arpeggio and Intermezzo were used to analyze interatomic interactions and visualize structural changes.
Datasets
The study primarily utilizes existing protein data bank (PDB) entries for homologous RNAP structures (PDB IDs: 5UH5 and 5UHC) as templates for comparative modeling. Additionally, a literature review was conducted to compile a dataset of 40 experimentally identified rifampin-resistant mutations in M. leprae from various studies, which were used for validation.
Key Insights and Ideas
- "Mutation Coolspots" for Drug Discovery: By mapping regions of the RNAP beta subunit that are least affected by mutations (termed "mutation coolspots"), the study identifies potential targets for novel small molecule inhibitors. These sites are less prone to developing resistance through mutation.
- Destabilization as a Key Indicator: The research strongly suggests that most mutations conferring rifampin resistance lead to a destabilization of the RNAP beta subunit, impacting its interaction with rifampin and/or RNA. This provides a unifying principle for understanding resistance mechanisms.
- Systematic Prediction Power: The in-silico saturation mutagenesis approach, covering all possible single-point mutations, offers a powerful and comprehensive way to explore the mutational landscape of a protein and predict functional consequences.
- Validation of Computational Tools: The study validates the utility of computational tools like mCSM by showing that experimentally identified resistance mutations largely correspond to predicted destabilizing effects.
Key Results
- Widespread Destabilizing Effects: Mutations in conserved residues lining the active-site cleft predominantly showed destabilizing effects, leading to increased solvent accessibility.
- Identification of Detrimental Mutations: Six specific residues (S437, G459, H451, P489, K884, and H1035) were identified as particularly detrimental, inducing significant destabilization of protein stability and affinities.
- Correlation with Experimental Data: 77.5% of experimentally identified rifampin-resistant mutations were predicted to destabilize the beta subunit, and most of these were located near the rifampin binding site.
- Dominance of Specific Substitutions: Substitutions to aspartate were found to predominantly destabilize the beta subunit-RNA affinity, while arginine substitutions were most common for destabilizing beta subunit-rifampin affinity.
Limitations and Future Work
- Experimental Validation Needed: While the computational predictions are robust, the authors acknowledge the need for experimental validation of the identified detrimental mutations and "mutation coolspots."
- Focus on Single Mutations: The study primarily focuses on single-point mutations. Future work could explore the impact of compensatory or co-evolving mutations within the entire RNAP holoenzyme complex.
- Computational Intensity: While faster than experimental methods, the computational saturation mutagenesis approach can still be resource-intensive. The authors mention that molecular dynamics simulations could further improve accuracy but are computationally demanding.
- Limited Experimental Data: The accuracy of predictions is somewhat limited by the availability of experimental data on stability changes for M. leprae RNAP mutations.
The authors suggest that further studies on the entire RNAP holoenzyme complex and experimental validation of the identified "mutation coolspots" are crucial next steps for advancing drug discovery and diagnostics for rifampin-resistant leprosy.
Summary updated